GSK to acquire clinical-stage biopharmaceutical company Affinivax for US$ 3.3 billion
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Subscribe To Our Newsletter & Stay Updated